COTY INC. (COTY) Spending and interest coverage
- R&D / revenue · 12 months: Value 2.09%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 0.80%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 2.09% | Research and development expense / revenue. Period ending 2026-06-30. $121.20M ÷ $5.81B × 100 ≈ 2.09% |
| Stock-based compensation / revenue · 12 months | 0.80% | Share-based compensation / revenue. Period ending 2026-06-30. $46.30M ÷ $5.81B × 100 ≈ 0.80% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 121.20M USD | Research and Development Expense |
| Revenue | 5.81B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 46.30M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -81.50M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $121.20M | $5.81B | $46.30M | $-81.50M | (m) | 2.09% | 0.80% | (m) | (m) |
| 2026-03-31 | (m) | $5.79B | $44.50M | $-23.30M | (m) | (m) | 0.77% | (m) | (m) |
| 2025-12-31 | (m) | $5.81B | $49.90M | $68.30M | (m) | (m) | 0.86% | (m) | (m) |
| 2025-09-30 | (m) | $5.80B | $47.50M | $188.30M | (m) | (m) | 0.82% | (m) | (m) |
| 2025-06-30 | $123.00M | $5.89B | $50.00M | $241.10M | (m) | 2.09% | 0.85% | (m) | (m) |
| 2025-03-31 | (m) | $6.00B | $63.10M | $260.30M | (m) | (m) | 1.05% | (m) | (m) |
| 2024-12-31 | (m) | $6.09B | $71.40M | $618.50M | (m) | (m) | 1.17% | (m) | (m) |
| 2024-09-30 | (m) | $6.15B | $76.10M | $587.00M | (m) | (m) | 1.24% | (m) | (m) |
| 2024-06-30 | $126.80M | $6.12B | $88.80M | $546.70M | (m) | 2.07% | 1.45% | (m) | (m) |
| 2024-03-31 | (m) | $6.11B | $107.40M | $641.00M | $260.60M | (m) | 1.76% | 2.46× | Reported |
| 2023-12-31 | (m) | $6.01B | $120.50M | $606.70M | $267.00M | (m) | 2.01% | 2.27× | Reported |
| 2023-09-30 | (m) | $5.81B | $134.50M | $569.30M | $270.30M | (m) | 2.32% | 2.11× | Reported |
| 2023-06-30 | $105.20M | $5.55B | $135.90M | $543.70M | $261.10M | 1.89% | 2.45% | 2.08× | Reported |
| 2023-03-31 | (m) | $5.37B | $130.10M | $337.30M | $243.60M | (m) | 2.42% | 1.38× | Reported |
| 2022-12-31 | (m) | $5.27B | $125.00M | $350.90M | $239.30M | (m) | 2.37% | 1.47× | Reported |
| 2022-09-30 | (m) | $5.32B | $118.40M | $395.60M | $236.00M | (m) | 2.22% | 1.68× | Reported |
| 2022-06-30 | $97.30M | $5.30B | $195.50M | $240.90M | $241.20M | 1.83% | 3.69% | 1.00× | Reported |
| 2022-03-31 | (m) | $5.20B | $165.30M | $320.10M | $245.90M | (m) | 3.18% | 1.30× | Reported |
| 2021-12-31 | (m) | $5.04B | $143.40M | $261.60M | $236.70M | (m) | 2.85% | 1.11× | Reported |
| 2021-09-30 | (m) | $4.88B | $131.10M | $34.60M | $235.60M | (m) | 2.69% | 0.15× | Reported |
| 2021-06-30 | $96.50M | $4.63B | $29.90M | $-48.60M | $231.80M | 2.08% | 0.65% | -0.21× | Reported |
| 2021-03-31 | (m) | $4.13B | $40.60M | $-970.90M | $231.10M | (m) | 0.98% | -4.20× | Reported |
| 2020-12-31 | (m) | $4.16B | $35.60M | $-1.27B | $238.20M | (m) | 0.86% | -5.33× | Reported |
| 2020-09-30 | (m) | $4.43B | $30.60M | $-1.37B | $231.10M | (m) | 0.69% | -5.91× | Reported |
| 2020-06-30 | $93.40M | $4.72B | $29.80M | $-1.24B | $233.30M | 1.98% | 0.63% | -5.30× | Reported |
| 2020-03-31 | (m) | $7.93B | $25.10M | $-2.83B | $289.70M | (m) | 0.32% | -9.77× | Reported |
| 2019-12-31 | (m) | $8.39B | $23.10M | $-2.48B | $297.80M | (m) | 0.28% | -8.34× | Reported |
| 2019-09-30 | (m) | $8.56B | $14.60M | $-3.32B | $305.60M | (m) | 0.17% | -10.88× | Reported |
| 2019-06-30 | $162.80M | $8.65B | $14.80M | $-3.47B | $302.50M | 1.88% | 0.17% | -11.48× | Reported |
| 2019-03-31 | (m) | (m) | $12.30M | $-804.00M | $297.90M | (m) | (m) | -2.70× | Reported |
| 2018-12-31 | (m) | (m) | $22.60M | $-868.80M | $296.60M | (m) | (m) | -2.93× | Reported |
| 2018-09-30 | (m) | (m) | $30.10M | $111.00M | $292.10M | (m) | (m) | 0.38× | Reported |
| 2018-06-30 | $174.60M | (m) | $30.60M | $161.20M | $287.10M | (m) | (m) | 0.56× | Reported |
| 2018-03-31 | (m) | (m) | $31.60M | $-56.00M | $274.20M | (m) | (m) | -0.20× | Reported |
| 2017-12-31 | (m) | (m) | $31.70M | $-268.40M | $257.70M | (m) | (m) | -1.04× | Reported |
| 2017-09-30 | (m) | (m) | $28.40M | $-455.50M | $247.30M | (m) | (m) | -1.84× | Reported |
| 2017-06-30 | $139.20M | (m) | $24.60M | $-437.80M | $219.60M | (m) | (m) | -1.99× | Reported |
| 2017-03-31 | (m) | (m) | $22.90M | $-161.70M | $197.40M | (m) | (m) | -0.82× | Reported |
| 2016-12-31 | (m) | (m) | $19.30M | $53.80M | $171.50M | (m) | (m) | 0.31× | Reported |
| 2016-09-30 | (m) | (m) | $15.80M | $218.90M | $137.60M | (m) | (m) | 1.59× | Reported |
| 2016-06-30 | (m) | (m) | $22.20M | $254.20M | $112.90M | (m) | (m) | 2.25× | Reported |
| 2016-03-31 | (m) | (m) | $43.10M | $233.70M | $89.60M | (m) | (m) | 2.61× | Reported |
| 2015-12-31 | (m) | (m) | $34.50M | $325.40M | $74.90M | (m) | (m) | 4.34× | Reported |
| 2015-09-30 | (m) | (m) | $40.00M | $356.70M | $67.00M | (m) | (m) | 5.32× | Reported |
| 2015-06-30 | (m) | (m) | $30.60M | $395.10M | $71.40M | (m) | (m) | 5.53× | Reported |
| 2015-03-31 | (m) | (m) | $17.00M | $407.10M | $73.00M | (m) | (m) | 5.58× | Reported |
| 2014-12-31 | (m) | (m) | $31.40M | $20.40M | $71.70M | (m) | (m) | 0.28× | Reported |
| 2014-09-30 | (m) | (m) | $32.70M | $-19.80M | $71.80M | (m) | (m) | -0.28× | Reported |
| 2014-06-30 | (m) | (m) | $46.80M | $25.70M | $69.80M | (m) | (m) | 0.37× | Reported |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | $144.40M | $394.40M | $77.20M | (m) | (m) | 5.11× | Reported |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | $142.60M | $-209.50M | $81.80M | (m) | (m) | -2.56× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EDGEWELL PERSONAL CARE Co (EPC) | United States | $1.261B | -13.27 |
| INTERPARFUMS INC (IPAR) | United States | $3.707B | 21.36 |
| SOLESENCE, INC. (SLSN) | United States | $0.058B | -25.13 |
| Axil Brands, Inc. (AXIL) | United States | $0.042B | 17.24 |
| UNITED GUARDIAN INC (UG) | United States | $0.034B | 13.30 |
| Caring Brands, Inc. (CABR) | United States | $0.013B | |
| BONK, INC. (BNKK) | United States | $0.011B | -0.14 |
| cbdMD, Inc. (YCBD) | United States | $0.005B | -2.59 |
| e.l.f. Beauty, Inc. (ELF) | United States | $5.934B | |
| Kenvue Inc. (KVUE) | United States | $33.844B | 22.14 |